Pazib 200MG Tablet, containing the active ingredient Pazopanib at a dosage of 200mg, is a targeted therapy primarily used in the treatment of advanced renal cell carcinoma (kidney cancer) and soft tissue sarcoma. This medication works by inhibiting multiple receptor tyrosine kinases, which play a crucial role in tumor growth and angiogenesis (the formation of new blood vessels that supply nutrients to tumors). The composition of Pazib includes Pazopanib as the active component, along with various excipients that aid in the tablet’s formulation and absorption. As a part of cancer treatment regimens, Pazib is often prescribed to patients who have not responded to other therapies, providing a vital option in the management of these challenging conditions. Its mechanism of action not only targets cancer cells but also helps in reducing the blood supply to tumors, thereby slowing their growth and spread.